Grifols (GRFS) Expected to Release Quarterly Earnings on Monday

Grifols (NASDAQ:GRFS) is expected to announce its Q3 2026 resultson Monday, November 2nd. Analysts expect Grifols to post earnings of $0.3202 per share and revenue of $2.21 billion for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 12:30 PM ET.

Grifols Stock Performance

Shares of NASDAQ GRFS traded down $0.04 during trading hours on Wednesday, reaching $8.06. 80,521 shares of the stock traded hands, compared to its average volume of 637,970. The company’s 50-day simple moving average is $7.59 and its two-hundred day simple moving average is $8.03. Grifols has a 52-week low of $6.96 and a 52-week high of $9.90.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings raised shares of Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, August 17th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. decreased their price objective on Grifols from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $9.00.

About Grifols

Grifols SA is a global healthcare company headquartered in Barcelona, Spain, specializing in plasma-derived medicines and diagnostic technologies. The company develops, manufactures and markets therapies made from human plasma, including immunoglobulins, albumin and coagulation factors used to treat immune deficiencies, bleeding disorders and other chronic conditions.

Grifols operates a vertically integrated plasma business that includes plasma donation centers, collection and fractionation facilities, research and development, manufacturing and distribution.